Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee

NCT06884865 is registered in ClinicalTrials.gov with Pacira Pharmaceuticals, Inc as lead sponsor.

NCT NCT06884865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06884865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee
Lead sponsor
Pacira Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
February 26, 2025
Completion date
July 31, 2032
Enrollment
135 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis (oa) of the knee